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ABSTRACT Cryptococcal meningoencephalitis is an urgent global health problem. Induction regimens using 14 days of ampho-
tericin B deoxycholate (dAmB) are considered the standard of care but may not be suitable for resource-poor settings. We inves-
tigated the efficacy of conventional and abbreviated regimens of dAmB for cryptococcal meningoencephalitis in both murine
and rabbit models of cryptococcal meningoencephalitis. We examined the extent to which immunological effectors contribute to
the antifungal effect. We bridged the results to humans as a first critical step to define regimens suitable for further study in clin-
ical trials. There were significant differences in the murine plasma-versus-cerebrum dAmB concentration-time profiles. dAmB
was detectable in the cerebrum throughout the experimental period, even following the administration of only three doses of
3 mg/kg. dAmB induced a fungistatic effect in the cerebrumwith a 2- to 3-log10 CFU/g reduction compared with controls. The
effect of 3 days of therapy was the same as that of daily therapy for 14 days. There was no evidence of increased numbers of CD3
CD4 or CD3 CD8 cells in treated mice to account for the persistent antifungal effect of an abbreviated regimen. The admin-
istration of dAmB at 1 mg/kg/day for 3 days was the same as daily therapy in rabbits. The bridging studies suggested that a hu-
man regimen of 0.7 mg/kg/day for 3 days resulted in nearly maximal antifungal activity in both the cerebrum and cerebrospinal
fluid. An abbreviated regimen (3 days of therapy) of dAmB appears to be just as effective as conventional induction therapy for
cryptococcal meningoencephalitis.
IMPORTANCE Cryptococcal meningitis is a significant and neglected infection that is associated with excessive morbidity and
mortality. In well-resourced health care settings, induction therapy with at least 2 weeks of amphotericin B deoxycholate
(dAmB) is advocated. Multiple clinical studies suggest that dAmB is the drug of choice for cryptococcal meningitis. In many
parts of the world where the burden of cryptococcal meningitis is highest, it is infeasible to administer dAmB for prolonged peri-
ods. This paper provides the experimental basis for the efficacy of abbreviated regimens of dAmB for cryptococcal meningitis.
The concept was explored in two well-validated laboratory animal models of cryptococcal meningitis, and the results were
bridged to humans by using a range of mathematical modeling techniques. A 3-day regimen is as effective as the standard 14-day
course. An abbreviated regimen is significantly more feasible andmay enable better antifungal therapy to be administered to
many patients with this frequently lethal disease.
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Cryptococcal meningitis is an important, neglected infectionthat continues to posemany therapeutic challenges. There are
few active drugs, a striking paucity of new agents in developmental
pipelines, and problems with the global supply of first-line agents
that are considered the standard of care in developed health care
settings.
In well-resourced health care settings, effective antifungal reg-
imens and combinations for cryptococcalmeningitis are relatively
well delineated. Induction regimens consist of 2 weeks of ampho-
tericin B deoxycholate (dAmB; Fungizone) at 0.7 to 1.0mg/kg/day
given intravenously (i.v.) in combination with flucytosine at
100 mg/kg/day given orally or i.v. in four divided doses. A lipid
preparation of dAmBmay be used, although there is less certainty
about the optimal regimen—this has recently been addressed by
us, as well as other investigators (1, 2). In resource-poor settings, it
is often not possible to administer long courses of i.v. dAmB safely
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because prolonged parenteral therapy is too expensive and/or
there are inadequate resources to monitor for and manage drug-
related toxicity. These obstacles are especially pertinent for many
parts of sub-Saharan Africa, which has a disproportionate share of
the world’s burden of cryptococcal meningitis. Thus, many pa-
tients do not receive the best antifungal regimens to ensure that
their clinical outcomes are optimized. Therefore, alternative and
feasible approaches are urgently required.
One potential approach to achieving better clinical outcomes
for cryptococcal meningitis in resource-poor settings is the use of
high-dose fluconazole alone or in combination with flucytosine
(3). Such a regimen is effective and has the advantage of being
orally bioavailable. Unfortunately, the outcomes of induction
with fluconazole-based regimens are still inferior to those ob-
tainedwith dAmB.However, phase II clinical data suggest that the
outcome of cryptococcal meningitis following a shortened induc-
tion regimen with dAmB in combination with other antifungal
agents may be favorable (4). In this study, we examined the effi-
cacy of abbreviated versus prolonged induction regimens of
dAmB monotherapy for cryptococcal meningoencephalitis. We
used two laboratory animal models of cryptococcal meningoen-
cephalitis to define the pharmacokinetic-pharmacodynamic (PK-
PD) relationships in both the cerebrum and cerebrospinal fluid
(CSF). We have bridged our results to humans to provide abbre-
viated regimens that may be feasible to use in even the most
resource-poor settings and can be further studied in clinical trials.
RESULTS
I.v. and intracisternal inoculation of mice and rabbits, respec-
tively, with C. neoformans results in reproducible meningoen-
cephalitis. There were progressive histopathological changes
throughout the cerebra of mice (Fig. 1). In the initial 24 h postin-
oculation, there were relatively few yeast cells visible in their cere-
bra, even though there was strong staining with an anticryptococ-
cal antibody (Fig. 1). In rabbits, the meninges were densely
infiltrated by organisms (Fig. 2). There was a logarithmic increase
in the fungal burden in the cerebra of untreated mice throughout
the first week, which then plateaued at approximately 6 to 7 log10
CFU/g cerebrum (Fig. 3). The estimate from the mathematical
model for POPMAX (the maximum fungal density in the cere-
brum) was 6.26 log10 CFU/g (Tables 1 and 2). Similarly, there was
a progressive logarithmic increase in the fungal density in the CSF
of rabbits, which increased in most of the animals to 5 to 6 log10
CFU/ml at the end of the experiment (Fig. 4). The rate of increase
was slower than that observed in mice (the Kgmax values for rab-
bits and mice were 0.063 and 0.096 log10 CFU/g/h, respectively
[Tables 1 and 2]). Interestingly, the intracisternal inoculation of
rabbits withCryptococcus neoformans also resulted in reproducible
encephalitis with a mean  standard error of the mean fungal
burden of 5.63 0.17 log10 CFU/g cerebrum (Fig. 4F).
Pharmacokinetics and pharmacodynamics of dAmB. The
pharmacokinetics of dAmB in mice and rabbits were well ac-
counted for by linear models. The most striking feature of the
pharmacokinetics of dAmB in mice was the extent of hysteresis
between plasma and the cerebrum (Fig. 3). The concentration of
dAmB progressively accumulated over the experimental period.
The prolonged mean residence time within the cerebrum also
accounted for the persistence of dAmBin the cerebrum following
the administration of only three doses (Fig. 3). A serial-sacrifice
experimental design was not possible with rabbits, meaning that it
was not possible to obtain robust estimates of the extent of drug
penetration of various subcompartments of the central nervous
system or the time course of concentrations at those sites. Never-
theless, it was possible to detect dAmB in both the cerebra and
meninges of at least some rabbits at the end of the experiment
(data not shown).
dAmB induced a dose-dependent decline in the fungal burden
within the cerebra of mice. A dosage of 0.1 mg/kg/day had little
effect compared with that in untreated controls, but the adminis-
tration of 1 and 3 mg/kg/day resulted in a 2- to 3-log decline in
fungal density relative to that in controls. The pharmacodynamics
of dAmB at 3mg/kg/day inmice are shown in Fig. 3. There was no
clear evidence of “fungicidal” antifungal activity within the cere-
brum (i.e., there was no evidence of a progressive decline in fungal
density) throughout the experimental period. Rather, dAmB re-
sulted in the prevention of inexorable fungal growth within the
cerebrum. The antifungal effects of daily dosing and an abbrevi-
ated regimen of 3 days were comparable (Fig. 3). The data and
mathematical model suggested that this observation could be ex-
plained by concentrations of dAmB that exceeded a threshold in
the cerebrum. The estimated C50g (i.e., the concentration of
dAmB in the cerebrum at which the suppression of growth is
half-maximal) was 0.02 g/g. For both daily administration and
the abbreviated regimen, this concentration was readily achieved
throughout the experimental periodwith a dosage of 3mg/kg/day.
Only a single dosage of 1 mg/kg/day was studied in rabbits—
this was based on numerous previous studies of dAmB in rabbits.
In those studies, after a single dose of dAmB, CSF levels of 2 to
10 ng/ml were measured over 24 h. Following multiple daily dos-
ing (6 days), the concentrations were approximately 6 ng/ml (5).
A daily regimen of dAmB at 1 mg/kg resulted in prompt fun-
gicidal activity within the CSF (Fig. 4B). Comparable fungicidal
activity was observedwith alternative regimens of 1mg/kg admin-
istered every 3 days and an abbreviated regimen of 1 mg/kg ad-
ministered 48, 72, and 96 h postinoculation. There was some an-
tifungal activity in at least some rabbits that received a single dose
of dAmB, but in all cases there was progressive fungal growth in
the CSF in the latter parts of the experimental period (Fig. 4E).
There were clear differences in the pharmacodynamics in the CSF
and the cerebrum. Despite a rapid decline and apparent steriliza-
tion of the CSF in many rabbits, there was persistent fungal infec-
tion in the cerebrum. The abbreviated regimen resulted in a fungal
burden in the cerebrum comparable to that obtained with daily
dosing (P  1.00; Fig. 4F). All treatment arms had a statistically
significantly lower fungal burden in the cerebrum than the con-
trols.
The persistent antifungal activity of an abbreviated dAmB
regimen is not caused by immunological effectors. The percent-
ages of CD3 CD4 and CD3 CD8 cells increased in the cere-
brum in the first 7 days of infection (Fig. 5). Treatment of mice
with dAmB at 3 mg/kg/day as both a daily and abbreviated course
resulted in a lower absolute number of T cells in the cerebrum
than in controls. There was some evidence of an inflammatory
infiltrate in untreated controls 7 days postinoculation (for exam-
ple, Fig. 1G). Studies using flow cytometry suggested that there
was a progressive increase in both CD3 CD4 and CD3 CD8
cells in the first week of infection (Fig. 5). At the end of the exper-
Livermore et al.
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FIG 1 The temporal course of cryptococcal meningoencephalitis in mice inoculated i.v. withC. neoformansH99. Small focal lesions containing a small number
of organisms early in the infection progressively enlarge throughout the experimental period. There is leaching of capsular material into the surrounding
parenchyma. Sections have been stained with hematoxylin and eosin or an anticryptococcal antibody. (A) One hour postinoculation;100magnification; scale
bar, 100 m. (B) One hour postinoculation; 400 magnification; scale bar, 25 m. (C) Twenty-four hours postinoculation; 200 magnification; scale bar,
50 m. (D) Seventy-two hours postinfection;200 magnification; scale bar, 50 m. (E and F) One hundred twenty hours postinfection;100 magnification;
scale bars, 100 m. (G and H) One hundred sixty-eight hours postinfection; 40 magnification; scale bars, 100 m. (I and J) Two hundred forty hours
postinfection;40 magnification; scale bars, 250 m.
Abbreviated dAmB Regimen for Cryptococcal Meningitis
January/February 2014 Volume 5 Issue 1 e00725-13 ® mbio.asm.org 3
 
m
bio.asm
.org
 o
n
 January 6, 2015 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
iment, there were significantly fewer T cells in the cerebra of
treated mice than in those of untreated controls (Fig. 5). There
were no differences in the number ofCD3CD4 orCD3CD8
cells following treatment with the daily versus the abbreviated
regimen (P 0.190 and 0.103 for CD3 CD4 and CD3 CD8
cells, respectively; Fig. 5C). Following treatmentwith dAmB, there
was no evidence of an inflammatory infiltrate on hematoxylin-
and-eosin staining or following immunohistochemical staining
for CD3 cells (Fig. 5D).
Abbreviated inductionregimensofdAmBarepredicted tobe
effective in humans. An abbreviated human regimen of dAmB at
0.7 mg/kg administered for 3 days was predicted to result in the
suppression of fungal growth within the human cerebrum for at
least 2 weeks (Fig. 6). This is a result of the long terminal half-life
of dAmB (65.19 h) and the implied hysteresis within a deep and
slowly equilibrating tissue site within the central nervous system.
Similarly, this same human regimen was predicted to result in
prompt fungicidal activity in the CSF (Fig. 6).
FIG 2 Pathological changes in the meninges of rabbits 7 days postinoculation of 1  108 CFU of C. neoformans into the cervical cistern. (A) Hematoxylin-
and-eosin staining; scale bar, 100 m. (B) Immunohistochemistry with staining with an anticryptococcal antibody; scale bar, 100 m.
FIG3 The pharmacokinetics and pharmacodynamics of dAmB at 3mg/kg againstC. neoformans in amurinemodel of cryptococcalmeningoencephalitis. There
is hysteresis in the plasma-versus-cerebrum pharmacokinetics (PK), with concentrations in the latter progressively increasing throughout the experimental
period. The administration of an abbreviated regimen results in persistently detectable concentrations in both plasma and the cerebrum, which accounts for the
persistent antifungal effect. For reference, the MIC for the isolate of C. neoformans used in these experiments was 0.125 mg/liter. Data are the mean standard
deviation of four mice. The solid line is the fit of the mathematical model to the data.
Livermore et al.
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DISCUSSION
Cryptococcal meningoencephalitis is a persistent global health
problem (7). There have been a number of studies conducted in
resource-poor settings that have attempted to identify optimal
induction regimens for cryptococcalmeningitis (for examples, see
references 3, 8, 9, and 10). Collectively, these studies suggest that
dAmB is the most potent fungicidal agent of the currently avail-
able compounds. An initial period of 2weeks of induction therapy
is generally used, although different durations have not been rig-
orously investigated. Longer-term therapy with all dAmB formu-
lations is potentially limited by adverse effects such as nephrotox-
icity (decreased renal function and tubular toxicity) and anemia
(11). These adverse events may preclude the use of otherwise op-
timal regimens of dAmB and thereby compromise clinical out-
comes. Shorter induction regimens with dAmB may be just as
effective and less toxic and enable its use in resource-poor settings.
The present study suggests that there is a threshold concentration
that is required for antifungal activity within the central nervous
system.
dAmB has been extensively studied for cryptococcal meningi-
tis. The first report of successful therapy was in 1957 (6). Very
early studies used a dosage of 1 to 1.5 mg/kg/day. While the dura-
tion of therapy was often not specified, a total cumulative dose of
3 g was often advocated. Subsequently, there has been a progres-
sive understanding and refinement of regimens of dAmB that are
safe and effective. Initially, a lower dAmB dosage of 0.3mg/kg was
studied in combination with flucytosine in an attempt to maxi-
mize efficacy and minimize dose-related toxicity (12). More re-
cently, dosages of 0.7 to 1 mg/kg/day have been studied (8, 9). A
higher dosage is more effective but also more toxic. Despite all of
these studies that have focused on safe and effective regimens, the
most appropriate duration of dAmB administration for induction
therapy has not been rigorously defined.
In resource-poor health care settings, an abbreviated regimen
of dAmBmay be feasible and potentially improve the clinical out-
come of patients with cryptococcal meningitis. An abbreviated
regimen of 5 to 7 days in combinationwith other antifungal agents
has been studied and appears effective (13). Such an approach
may have a number of advantages in terms of reduced cost and
reduced toxicity and promote its use in resource-poor health care
settings. dAmB could potentially be given for 3 days without in-
tensive monitoring of renal function and electrolytes. Patients
could be immediately switched to fluconazole, or alternatively, an
abbreviated regimen of dAmB could be administered on a “flu-
conazole backbone.”
The reason an abbreviated regimen of dAmB appears to be
effective can be understood on pharmacokinetic grounds. On the
basis of the experimental evidence obtained with mice, it is un-
likely that an immune-mediated antifungal effect is responsible
for its persistent antifungal activity following cessation of dosing.
The murine pharmacokinetic studies suggest that dAmB progres-
sively accumulates in the brain despite plasma concentrations be-
ing at a “steady state” (i.e., there was evidence of significant hys-
teresis). The physicochemical properties of dAmBmay enable it to
“stick” in the lipid-rich cerebrum and not be readily released back
into the circulation. Drug concentrations could conceivably be
higher in focally abnormal areas in the parenchyma, where there is
undoubtedly disruption of the blood-brain-barrier (for example,
Fig. 1). As expected, we could not reliably measure amphotericin
in theCSF of rabbits. The drugwas detectablewithin themeninges
of at least some rabbits but not in a reliable manner. This is po-
tentially because of the friable nature of this tissue and concentra-
tions that are relatively close to the analytical sensitivity of the
assay. Nevertheless, the meninges are the subcompartment that is
likely to be the most relevant for a detailed understanding of the
efficacy of dAmB for cryptococcal meningitis in both rabbits and
humans.
The conclusions of this study are predicated on comparable
dAmB penetration of the various subcompartments of the central
nervous system (i.e., the cerebrum and meninges) in laboratory
animal models and humans. Definitive clinical data that enable
such an estimate are unlikely to be forthcoming because of obvi-
ous ethical constraints (a brain biopsy is not a routine component
of clinical care for patientswith cryptococcalmeningitis). Autopsy
studies may be possible but are difficult to conduct, and the qual-
ity of the data obtained is often dubious. Such studies enable only
a point estimate of penetration (i.e., a simple ratio of plasma-to-
brain drug concentrations). These inherent limitations are some
of the reasons we chose to use two experimental models of cryp-
tococcal meningoencephalitis to address the pharmacodynamics
of an abbreviated regimen of dAmB.
This study highlights pharmacodynamic differences between
the cerebrum and CSF. Cryptococcal meningitis is more accu-
rately referred to as meningoencephalitis to reflect the fact that
there is involvement of the meninges and CSF, as well as the cere-
bral parenchyma (14). The rabbit studies suggest that these sub-
compartments are distinct in terms of their response to dAmB.
Both daily and abbreviated regimens of dAmB result in prompt
fungicidal activity in the CSF, but there is a significant residual
burden within the cerebral parenchyma. The clinical importance
of this finding is not clear. While it is possible that a portion of
morbidity and mortality is related to suboptimally treated paren-
chymal disease, results of clinical trials suggest that the rate of
TABLE 1 Mean parameter values and standard deviations for mice and
rabbitsa
Parameter
Mean (SD)
Mice Rabbits
Ka (h1) 3.07 (0.15)
SCL (liters/h) 0.0018 (0.00007) 0.32 (0.16)
Vc (liters) 0.01 (0.00028) 1.64 (1.00)
K12 (h1) 2.53 (0.046) 1.12 (1.24)
K21 (h1) 29.29 (0.16) 29.45 (0.60)
K23 (h1) 1.10 (0.09) 1.88 (1.27)
K32 (h1) 0.004 (0.87 1010) 0.042 (0.015)
Kcp (h1) 21.90 (0.59) 21.56 (4.27)
Kpc (h1) 2.87 (0.31) 10.72 (9.06)
Vbrain (liters) 0.60 (0.69) 0.077 (0.028)
Kgmax (log10 CFU/g/h) 0.096 (0.008) 0.063 (0.028)
Hg 4.68 (1.52) 5.99 (5.43)
C50g (mg/liter) 0.02 (0.006) 0.154 (0.073)
POPMAX
(CFU/g cerebrum)
1,822,010 (655,459) 2,776,560 (4,271,150)
Kkmax (log10 CFU/g/h) 0.043 (0.043)
Hk 9.48 (5.66)
C50k (mg/liter) 0.178 (0.035)
Initial condition
(CFU/g cerebrum)
101.20 (2.28) 57.15 (38.54)
a See the text for definitions of parameter values.
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decline of yeast in the CSF is an important prognostic marker and
is associated with overall survival (9, 15).
Clinical studies are now required to further investigate the util-
ity of shortened dAmB-based induction regimens in the most
resource-limited centers, where fluconazole currently remains the
mainstay of therapy, building on prior phase II trials (4, 13) and
one ongoing phase III trial comparing 7 days with the standard
14 days of dAmB-based induction (ISRCTN45035509). These
shortened regimens could be administered as monotherapy or in
combination with other antifungal agents. These studies could
incorporate the clinical response anddeath as endpoints to further
investigate the effect of the duration of dAmB therapy on the
outcome. This study is a further example of the use of PK-PD
analyses and bridging studies to generate clinically relevant hy-
potheses. Such a paradigm is a way that therapeutic advances can
be made while minimizing risk.
MATERIALS AND METHODS
Organism and MIC. The challenge strain for all experiments was C. neo-
formans var. grubii H99 (ATCC 208821). The organism was stored at
80°C on beads and retrieved prior to each experiment. For rabbit exper-
FIG 4 Effects of various regimens of dAmB for experimental cryptococcal meningoencephalitis in rabbits. dAmB at 1 mg/kg was administered daily (B), every
third day (C), as an abbreviated regimen for 3 consecutive days (D), or once (E). The solid arrows show the times of drug administration. The data in panels A
to E represent the time course of infection in the CSF. Each line represents the fungal burden in an individual rabbit. Panel F shows the fungal density in the
cerebrum at the end of the experiment. Each bar represents the mean fungal density  the standard error of the mean. There is no statistically significant
difference in cerebral fungal density between rabbits that received daily therapy and those that received an abbreviated regimen of 1mg/kg at 48, 72, and 96 h after
inoculation. *, P 1.00 (not significant); **, P 0.006; ***, P 0.001; ****, P 0.001; *****, P 1.00 (not significant).
TABLE 2 Mean and median parameter values and estimates of the
standard deviations for the population pharmacokinetic model fitted to
data obtained from healthy volunteers receiving dAmB at 0.6 mg/kga
Parameter Mean Median SD
SCL (liters/h) 1.34 1.33 0.09
Vc (liters) 30.8 26.89 5.25
Kcp (h1) 0.11 0.15 0.015
Kpc (h1) 0.05 0.15 0.0024
a See the text for definitions of parameter values.
Livermore et al.
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iments (see below), there were some concerns based on preliminary ex-
periments that the organism had become less virulent as a result of stor-
age. Consequently, the yeast was passaged once in a single mouse.
Following i.v. inoculation, the mouse was kept for 10 days before being
sacrificed. The brain was removed, homogenized, and plated. The yeast was
recovered on Sabouraud agar before being refrozen on beads at80°C.
For experiments with mice and rabbits, a suspension containing the
desired density (1  108 CFU/ml) of organisms was prepared in
phosphate-buffered saline (PBS; Invitrogen) from yeast cells incubated in
20 ml yeast extract-peptone-dextrose (YPD) broth on an orbital shaker
and incubated at 30°C for 48 h.
The MIC of dAmB was determined from three independently con-
FIG 5 The effect of an abbreviated regimen of dAmB is not due to an immune-mediated effect. Panel A shows the gating strategy; panel B shows the time course
of fungal density in the cerebrums ofmice infectedwithC. neoformans. Progressive logarithmic growthwas seen in controls (open triangles). The antifungal effect
of an abbreviated regimen of dAmB at 3 mg/kg (open circles) is comparable to daily dosing with 3 mg/kg (open squares). Data are the mean  the standard
deviation of three or fourmice. (C) The absolute numbers of CD3CD4 andCD3CD8cells in the cerebrums ofmice infectedwithC. neoformans. There was
a progressive increase in both CD3CD4 and CD3CD4cells in untreated infected controls but no increase in drug-treatedmice. *, P 0.001; **, P 0.003;
***, P 0.190 (not significant); §, P 0.001; §§, P 0.002; §§§, P 0.103 (not significant). (D) No evidence of an inflammatory infiltrate in mice treated with
dAmB (top twomicrographs; scale bars, 25 and 50m, respectively) or in infected untreated controls using immunohistochemistry (bottom right micrograph).
The bottom left micrograph is a positive control.
Abbreviated dAmB Regimen for Cryptococcal Meningitis
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ducted experiments using Clinical Laboratory Standards Institute (CLSI)
methodology and was 0.125 mg/liter on each occasion.
Laboratory animal models of cryptococcal meningitis. All labora-
tory animal models were performed under project licenses PPL40/3101
(The University of Manchester, Manchester, United Kingdom) and 40/
3630 (University of Liverpool, Liverpool, United Kingdom). The proto-
cols used were approved by ethics committees at the respective institu-
tions.
A previously described murine model of cryptococcal meningoen-
cephalitis was initially used to define the pharmacokinetic and pharma-
codynamic relationships of dAmB (16).Mice were inoculated i.v. with 3.8
 105 organisms via the lateral tail vein in 0.25 ml PBS (Invitrogen, Pais-
ley, United Kingdom). The desired inoculum was checked with quantita-
tive cultures. No immunosuppression was used at any point in the exper-
iment since mice are innately susceptible to the development of
disseminated cryptococcosis.
Key experimental observations inmice were confirmed in a previously
described rabbit model of cryptococcal meningoencephalitis (17), with
minor modification of the agents used to induce general anesthesia (see
below). Briefly, male New ZealandWhite rabbits weighing approximately
2 kg were used. Rabbits were inoculated with a cryptococcal suspension
directly into the cisternamagna. A target of 1 108 CFU in a 1-ml volume
was administered. Rabbits were immunosuppressed with cortisone ace-
tate at 7.5 mg/kg given intramuscularly (i.m.), which was started on day
1 relative to inoculation and then administered daily throughout the
experimental period. CSF (approximately 1 ml) was removed at 48, 96,
144, 192, 240, and 288 h postinoculation via an intracisternal tap with a
23-gauge needle. Plasma samples for pharmacokinetic analyses were ob-
tained from the lateral ear vein. All procedures were performed under
general anesthesia, which was induced with fentanyl-fluanisone (Hyp-
norm) at 0.3 ml/kg given i.m., followed by diazepam at 0.375 mg/kg.
Naloxone at 0.1 mg/kg was used as a reversal agent if required.
Drug. dAmB was diluted to the desired concentration with 5% glu-
cose. The specified dosage was administered to mice intraperitoneally
(i.p.). Therapy was initiated at 24 h postinoculation and administered
every 24 h thereafter for the designed duration of therapy. The dosage
effects of dAmB at 0.1, 1, and 3 mg/kg were studied. dAmB was adminis-
tered to each rabbit i.v. as a slow push via the lateral ear vein. Treatment
was commenced 48 h after the intracisternal inoculation of yeast cells and
administered every 24 h. On the basis of multiple previous experimental
studies of dAmB in rabbits, a single clinically relevant regimen of 1 mg/
kg/day was studied (18). The duration of therapy varied from experiment
to experiment.
Pharmacokinetic andpharmacodynamic studieswithmice andrab-
bits. A serial-sacrifice design was used to estimate the murine pharmaco-
kinetics and pharmacodynamics of dAmB. Three or four mice were used
for each dose and time point. Plasma was obtained by terminal cardiac
puncture, which was performed under anesthesia with 5% isoflurane
(Baxter, Newbury, United Kingdom). Samples were collected throughout
the first and fourth dosing intervals at 1, 3, 6, and 24 h and as trough
concentrations at later time points. After sacrifice with pentobarbitone,
the brain was removed and sectioned in a sagittal plane. One cerebral
hemisphere was used to quantify the fungal burden, while the other was
used to estimate cerebral concentrations of dAmB. Each half of the sec-
tioned brain was placed in two separate sterile plastic bags. For the phar-
macodynamic experiments, the brain was homogenized by using direct
pressure and then serially diluted in PBS. These 10-fold dilutions were
then plated onto Sabouraud agar and incubated at 30°C for 48 to 72 h to
enable the fungal burden to be estimated. The other half was frozen at
80°C to enable the quantification of drug concentrations.
The fungal burden in theCSF of rabbits was estimated by placing serial
samples of CSF on YPD agar (preliminary experiments suggested that the
recovery and rate of growth of yeast cells were better on YPD than on
Sabouraud agar). Plasma samples to enable the estimation of plasma
FIG 6 Bridging from experimental models (mice and rabbits) to humans. The murine pharmacokinetics (A) and rabbit pharmacokinetics (C) have been
“humanized” so they approximate a human receiving dAmB at 0.7mg/kg. The predicted pharmacodynamic output from the respectivemathematicalmodels for
mice (B) and rabbits (D) is shown. The pharmacodynamic outputs formice and rabbits are the fungal densities in the cerebrum and CSF, respectively. The effect
relative to controls is shown. The broken line at the bottom of panel D is the limit of detection (1 log10 CFU/ml).
Livermore et al.
8 ® mbio.asm.org January/February 2014 Volume 5 Issue 1 e00725-13
 
m
bio.asm
.org
 o
n
 January 6, 2015 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
pharmacokinetics were obtained on days 1 and 7. At the end of the exper-
iment, all rabbits were sacrificed and their brains were removed. Their
cerebra were homogenized and submitted for quantitative cultures.
MeasurementofdAmBconcentrations inplasmaand the cerebrum.
DAmB concentrations in plasma (mouse and rabbit) and cerebrum
(mouse) samples weremeasured by high-performance liquid chromatog-
raphy with a Shimadzu Prominence (Shimadzu) and a Varian Pursuit C18
5-m column (50 by 2.0 mm; Varian Inc.). The injection volume was
75 l. A standard curve was constructed in the respective matrix from
stock solutions of dAmB (Sigma) at 1,000 mg/liter in methanol (Fisher
Scientific). The internal standard was piroxicam at 0.1 mg/liter (Sigma).
The starting mobile phase was 80%A, consisting of 1% (vol/vol) aqueous
formic acid (Fisher Scientific), and 20% B, consisting of 1% (vol/vol)
formic acid in acetonitrile (Fisher Scientific). A gradient was used with
progression over 9.5 min from the starting conditions to 30% solution A.
The flow rate was 0.8 ml/min. DAmB and the internal standard were
detected by using UV light at 385 nm; they eluted after 4.1 and 2.3 min,
respectively. The coefficient of variation was 6% over a concentration
range 0.1 to 100 mg/liter. The limit of detection was 0.05 mg/liter. The
intra- and interday variations were8%.
Histology and immunohistochemistry. The cerebrum was fixed in
10% neutral buffered formalin, cryoprotected in sucrose, and embedded
in OCT freezing medium, and 5-m-thick sections were cut. Tissue sec-
tions were treated with peroxidase solution (Envison kit; DakoCytoma-
tion, Carpinteria, CA) to block endogenous peroxidase activity. A 1.5%
goat serum protein block was applied to reduce nonspecific binding. Sec-
tions were incubated with an anti-Cryptococcusmonoclonal antibody (1:
1,000 dilution; Mybiosource, San Diego, CA). Slides were reacted with a
peroxidase-labeled anti-mouse polymer (Envison kit; DakoCytoma-
tion, Carpinteria, CA). Antibody-antigen complexes were visualized by
using a 3,3=-diaminobenzidine chromogen substrate (DakoCytomation,
Carpinteria, CA) for the peroxidase reaction. Slides were counterstained
with hematoxylin (Richard-Allan Scientific, Kalamazoo, MI).
Immunohistochemical analysis to visualize CD3 cells in the cere-
brum was performed by a previously described method. Briefly, murine
cerebrum was fixed in xylene and dried in ethanol before being blocked
with peroxidase (Dako Real Peroxidase Blocking Solution). Sections were
incubated with a rabbit anti-human CD3 polyclonal antibody (Dako
A0452), which is a pan-T-cell marker for the detection of normal and
neoplastic T cells that cross-reacts with murine T cells (19). Slides were
then reacted with a peroxidase-labeled anti-rabbit polymer (Envison
System-HRP kit; Dako). Antibody-antigen complexes were visualized by
using a 3,3=-diaminobenzidine chromogen substrate for the peroxidase
reaction.
Immunological response to infection. The immunological response
to disseminated cryptococcal infection in the cerebrum was investigated
to estimate its potential contribution to the antifungal effect. These exper-
iments were performed only withmice—the necessary antibodies for flow
cytometry and immunohistochemistry are readily available for mice but
not for rabbits.
Mice were sacrificed by exposure to a rising concentration of CO2.
Subsequently, blood was replaced after death with PBS that was calcium
andmagnesium free. The brain was excised and cut into small pieces with
a scalpel. The cerebrumwas digested with 3ml of a 0.2-mg/ml collagenase
solution (Sigma) andDNase (200U/brain; Sigma) at 37°C for 30min. The
reaction was stopped by the addition of 1:100 EDTA (0.5 M), followed by
incubated for a further 5min at 37°C. The cell suspensionwas washed and
cells were suspended in 37% Percoll and underlayered with 70% Percoll.
The sample was centrifuged at 600 g for 30 min. Lymphocytes isolated
from the interface were washed and resuspended in RPMI medium.
Cells were blocked with Fc block (BD Biosciences) for 15 min at 4°C.
Cells were washed in FACS wash (PBS, 1% fetal calf serum, 0.1% sodium
azide) and then incubated with an antibody mixture (CD3e-fluorescein
isothiocyanate [145-2C11; eBioscience, Hatfield, United Kingdom],
CD4-APC [RM4-5; eBioscience], and CD8-PE-Cy5 [53-6.7; BD Biosci-
ences]) for 30min at 4°C. Cells were washed and resuspended in FACS fix
(PBS, 1% paraformaldehyde) before being analyzed with an LSRII flow
cytometer (BD Biosciences) and FlowJo software (TreeStar Inc., Ashland,
OR).
Mathematical modeling. The mathematical model was fitted to the
entire murine data set by using a population methodology. The nonpara-
metric adaptive grid (NPAG) program (20) was used. The pharmacoki-
netic and pharmacodynamic data were weighted after initially fitting the
same model by using the maximum-likelihood estimator in ADAPT 5
(21) (as previously described—see, for example, reference 22). The struc-
tural mathematical model consisted of the following six inhomogeneous
differential equations:
dX(1)
dt
 B(1) Ka X(1) (1)
dX(2)
dt
SCL
Vc
 Kcp Kce X(2) Ka X(1) Kec X(3)
 Kpc X(5) (2)
dX(3)
dt
Kec X(3) Kce X(2) Keb X(3) Kbe X(4)
(3)
dX(4)
dt
 Keb X(3) Kbe X(4) (4)
dX(5)
dt
Kpc X(5) Kcp X(2) (5)
dN
dt
 Kgmax 1 
X(4)
Vbrain
Hg
X(4)
Vbrain
Hg
 C50g
Hg 1 NPOPMAX
 N (6)
Where X(1), X(2), X(3), X(4), and X(5) represent the amounts of
dAmB (milligrams) in the peritoneum, central compartment, cerebral
endothelium, central tissue, and peripheral compartment, respectively.
B(1) represents the injection of dAmB (milligrams) into the peritoneums
of the mice; Ka is the first-order rate constant connecting the peritoneal
cavity with the central compartment; Kce, Kec, Keb, Kbe, Kcp, and Kpc rep-
resent the first-order rate constants connecting the various compart-
ments; Kgmax is the maximum rate of growth in the brain; Vbrain is the
volume of the brain; C50g is the concentration of dAmB in the brain at
which there is half-maximal inhibition of growth; POPMAX is the maxi-
mum theoretical density of organisms in the brain; N is the number of
organisms in the cerebrum; andHg is the slope function. SCL is the clear-
ance of drug (liters/h), and Vc is the volume of central compartment
(liters).
Equation 1 describes themovement of drug out of the peritoneumand
into the central compartment (i.e., plasma). Equation 2 describes the
movement of dAmB into and out of the central compartment (plasma).
Equations 3 and 4 describe the movement of the drug into deep compart-
ments within the brain. Equation 5 describes the movement of the drug
into and out of the peripheral compartment (i.e., everything except the
brain). Equation 6 describes the pharmacodynamics of dAmB. This equa-
tion contains terms that describe capacity-limited fungal growth in the
brain and the drug-induced suppression of fungal growth.
Several points about the construction and fitting of this mathematical
model to the murine data deserve emphasis. (i) The plasma and brain
pharmacokinetic data were discordant (i.e., there was hysteresis), which
required several deep pharmacokinetic compartments to enable this to be
described; and (ii) we did not observe fungicidal activity in the cerebrum.
Therefore, we did not include a term that described a decline in log10
CFU/g (as opposed to rabbits [see below]).
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A similar mathematical model was used to describe the PK-PD data
from rabbits, although there were some differences from mice. Most no-
tably, (i) dAmB was administered as an i.v. push directly into the central
compartment. (ii) There were no temporalmeasurements of dAmB in the
cerebra ormeninges of rabbits (and dAmBwas not detectable in the CSF);
consequently, we did not have good estimates of the shape of the
concentration-time profile of dAmB within the central nervous system.
(iii) The equation describing the pharmacodynamics of dAmB included
an extra term that described drug-induced fungal killing (i.e., fungicidal
activity). The equation describing the drug’s pharmacokinetics and phar-
macodynamics in rabbits is as follows:
dN
dt
 Kgmax 1 
X(2)
Vbrain
Hg
X(2)
Vbrain
Hg
 C50g
Hg 1 NPOPMAX
 N Kkillmax 
X(2)
Vbrain
Hk
X(2)
Vbrain
Hk
 C50k
Hk N
Where X(2) is the amount of dAmB in the central compartment (mil-
ligrams). There is an extra term that describes the dAmB-induced killing.
Kkillmax is the maximum rate of drug-induced killing, Hk is the slope
function,Vbrain is the volume of the brain, and C50k is the concentration
of the drug in the brain at which killing is half-maximal.
Bridging frommice and rabbits tohumans.Thepharmacokinetics of
dAmB in adult volunteers were determined from previously published
data (23). Five patients received 0.6 mg/kg of dAmB as an i.v. infusion
once-over a 2-h period. A standard two-compartment pharmacokinetic
model was fitted to the data by using NPAG. The fit of the model to the
data was assessed by using the same criteria as described above for the
laboratory animal models of infection.
The clinical implications of the experimental data were explored by
humanizing the murine and rabbit pharmacokinetics in silico. The pro-
gram BestDose was used to estimate the dosages needed to be adminis-
tered to both mice and rabbits that would result in a plasma pharmacoki-
netic profile equivalent to that for humans receiving 0.7 mg/kg. The
mathematicalmodels fitted tomice and rabbits were then used to estimate
the antifungal effect of each regimen.
Statistics. Differences in the fungal burden in the cerebra of rabbits
and the number of T cells in the cerebra of mice were determined by
analysis of variance with a Bonferroni correction as appropriate. All cal-
culations were performed with SYSTAT version 11.
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